Skip to main content

AstraZeneca, Emergent BioSolutions sign $87M deal to produce U.S. supply of COVID-19 vaccine | FiercePharma

By June 15, 2020News
AstraZeneca Emergent BioSolutions sign 87M deal to produce U S supply of COVID 19 vaccine FiercePharma

AstraZeneca Emergent BioSolutions sign 87M deal to produce U S supply of COVID 19 vaccine FiercePharma

AstraZeneca made waves last week when it signed a massive $750 million deal to ramp production of a University of Oxford COVID-19 vaccine up to 2 billion doses per year. Now, as part of a Trump administration effort to get shots into U.S. hands as soon as possible, AstraZeneca has agreed to another major manufacturing tie-up.

Image: AstraZeneca agreed to dole out $750 million last week to boost its COVID-19 shot capacity to more than 2 billion doses. (AstraZeneca)

{iframe}https://www.fiercepharma.com/manufacturing/astrazeneca-emergent-biosolutions-sign-87m-deal-to-produce-u-s-supply-covid-vaccine{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.